News
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Contact Us
Breakpoint Therapeutics GmbH
Essener Bogen 7
22419 Hamburg (Germany)
Telefon: +49 40 56081 180
E-mail: info@breakpointtx.com
Impressum
Registergericht: Hamburg
Registernummer: HRB 155717
Umsatzsteuer-Identifikationsnummer: DE 324 797 830
Geschäftsführer / Managing Directors
Dr. Daniel Speidel and Jonathan Hollick
Breakpoint To Present At DDR Inhibitors Summit, 2023
Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.
BVF Partners L.P. Joins Breakpoint’s Investor Syndicate
Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.
Dr. Juan Jaen Joins Breakpoint’s Advisory Board
Breakpoint welcomed Dr. Juan Jaen to its Advisory Board, adding his nearly 40 years of experience at the forefront of drug discovery and development to the company’s resources. He is Co-Founder, President, and member of the Board of Directors of Arcus Biosciences. Prior to founding Arcus, Juan was Co-Founder of Flexus Biosciences and before that […]